Biontech SE
BNTX105.095USD
+3.075+3.01%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
25.22BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Biontech SE Unternehmen
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Unternehmensinformationen
Unternehmens-codeBNTX
Name des UnternehmensBiontech SE
IPO-datumOct 10, 2019
Gegründet am2019
CEOProf. Ugur Sahin, M.D.
Anzahl der mitarbeiter6772
WertpapierartDepository Receipt
GeschäftsjahresendeOct 10
AddresseAn der Goldgrube 12
StadtMAINZ
BörseNASDAQ Global Select Consolidated
LandGermany
Postleitzahl55131
Telefon4949613190840
Websitehttps://www.biontech.com/
Unternehmens-codeBNTX
IPO-datumOct 10, 2019
Gegründet am2019
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
767.54K
+1.69%
Mr. Ryan Richardson
Mr. Ryan Richardson
Chief Strategy Officer, Member of the Management Board
Chief Strategy Officer, Member of the Management Board
26.55K
+80.66%
Mr. Jens Holstein
Mr. Jens Holstein
Chief Financial Officer, Member of the Management Board
Chief Financial Officer, Member of the Management Board
1.62K
--
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
790.00
--
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Prof. Anja Morawietz, Ph.D.
Prof. Anja Morawietz, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
240.00
--
Mr. Helmut Jeggle
Mr. Helmut Jeggle
Independent Chairman of the Supervisory Board
Independent Chairman of the Supervisory Board
--
--
Dr. Oezlem Tuereci, M.D.
Dr. Oezlem Tuereci, M.D.
Chief Medical Office, Member of the Management Board
Chief Medical Office, Member of the Management Board
--
--
Ms. Baroness Nicola Blackwood
Ms. Baroness Nicola Blackwood
Member of the Supervisory Board
Member of the Supervisory Board
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Sierk Poetting, Ph.D.
Dr. Sierk Poetting, Ph.D.
Chief Operating Officer, Member of the Management Board
Chief Operating Officer, Member of the Management Board
767.54K
+1.69%
Mr. Ryan Richardson
Mr. Ryan Richardson
Chief Strategy Officer, Member of the Management Board
Chief Strategy Officer, Member of the Management Board
26.55K
+80.66%
Mr. Jens Holstein
Mr. Jens Holstein
Chief Financial Officer, Member of the Management Board
Chief Financial Officer, Member of the Management Board
1.62K
--
Dr. Ulrich Wandschneider, Ph.D.
Dr. Ulrich Wandschneider, Ph.D.
Independent Deputy Chairman of the Supervisory Board
Independent Deputy Chairman of the Supervisory Board
1.48K
--
Mr. James Ryan
Mr. James Ryan
Member of the Management Board, Chief Legal Officer
Member of the Management Board, Chief Legal Officer
790.00
--
Prof. Rudolf Staudigl, Ph.D.
Prof. Rudolf Staudigl, Ph.D.
Independent Member of the Supervisory Board
Independent Member of the Supervisory Board
400.00
--
Umsatzaufteilung
Währung: EURUpdate-Zeit: Wed, Mar 12
Währung: EURUpdate-Zeit: Wed, Mar 12
FY2019
FY2018
FY2017
Nach GeschäftsbereichEUR
Name
Umsatz
Anteil
Collaboration Revenue
84.43M
77.75%
Revenues from Other Sales Transactions
24.16M
22.25%
Keine Daten
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichEUR
Name
Umsatz
Anteil
Collaboration Revenue
84.43M
77.75%
Revenues from Other Sales Transactions
24.16M
22.25%
Aktionäre
Update-Zeit: Thu, Mar 13
Update-Zeit: Thu, Mar 13
Aktionärsstatistik
Art
Aktionärsstatistik
Aktionäre
Anteil
AT Impf GmbH
42.44%
Medine GmbH
16.85%
Baillie Gifford & Co.
3.43%
Fidelity Management & Research Company LLC
2.69%
Flossbach von Storch AG
1.84%
Other
32.76%
Aktionärsstatistik
Aktionäre
Anteil
AT Impf GmbH
42.44%
Medine GmbH
16.85%
Baillie Gifford & Co.
3.43%
Fidelity Management & Research Company LLC
2.69%
Flossbach von Storch AG
1.84%
Other
32.76%
Art
Aktionäre
Anteil
Corporation
60.82%
Investment Advisor
15.74%
Investment Advisor/Hedge Fund
3.45%
Individual Investor
2.41%
Hedge Fund
0.93%
Sovereign Wealth Fund
0.75%
Research Firm
0.65%
Pension Fund
0.21%
Bank and Trust
0.18%
Other
14.86%
Institutionelle Beteiligung
Update-Zeit: Sun, Jan 19
Update-Zeit: Sun, Jan 19
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
822
205.15M
85.49%
+3.95M
2024Q4
869
205.33M
85.56%
+3.19M
2024Q3
843
197.46M
82.52%
-2.61M
2024Q2
819
194.42M
81.78%
-7.50M
2024Q1
835
193.57M
81.42%
-10.02M
2023Q4
897
193.24M
81.29%
-7.90M
2023Q3
920
192.71M
79.62%
-7.47M
2023Q2
940
195.49M
80.61%
-8.54M
2023Q1
953
197.88M
81.52%
-6.52M
2022Q4
937
198.79M
81.74%
-3.98M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
AT Impf GmbH
101.85M
42.44%
-636.54K
-0.62%
Dec 31, 2024
Medine GmbH
40.43M
16.85%
-7.37K
-0.02%
Dec 31, 2024
Baillie Gifford & Co.
8.22M
3.43%
-87.49K
-1.05%
Dec 31, 2024
Fidelity Management & Research Company LLC
6.45M
2.69%
+1.27M
+24.48%
Dec 31, 2024
Flossbach von Storch AG
4.41M
1.84%
+47.24K
+1.08%
Dec 31, 2024
PRIMECAP Management Company
4.30M
1.79%
-220.70K
-4.89%
Dec 31, 2024
Pfizer Inc
3.66M
1.52%
+3.66M
--
Dec 31, 2024
Sahin (Ugur MD)
2.77M
1.16%
+1.92M
+224.09%
Dec 31, 2024
Temasek Holdings Pte. Ltd.
1.81M
0.75%
--
--
Dec 31, 2024
Wolfgang (Jeggle Helmut)
1.43M
0.59%
-100.00K
-6.55%
Dec 31, 2024
Mehr Anzeigen
Verbundene ETFs
Update-Zeit: Sun, Apr 6
Update-Zeit: Sun, Apr 6
Name
Anteil
Global X Genomics & Biotechnology ETF
4.75%
Langar Global HealthTech ETF
4.42%
iShares Genomics Immunology and Healthcare ETF
4.13%
First Trust NYSE Arca Biotechnology Index Fund
2.86%
Franklin Genomic Advancements ETF
2.33%
VanEck Biotech ETF
2.2%
Range Cancer Immunotherapy ETF
1.61%
Virtus LifeSci Biotech Products ETF
1.51%
iShares Biotechnology ETF
1.38%
First Trust International Equity Opportunities ETF
1.33%
Mehr Anzeigen
Global X Genomics & Biotechnology ETF
Anteil4.75%
Langar Global HealthTech ETF
Anteil4.42%
iShares Genomics Immunology and Healthcare ETF
Anteil4.13%
First Trust NYSE Arca Biotechnology Index Fund
Anteil2.86%
Franklin Genomic Advancements ETF
Anteil2.33%
VanEck Biotech ETF
Anteil2.2%
Range Cancer Immunotherapy ETF
Anteil1.61%
Virtus LifeSci Biotech Products ETF
Anteil1.51%
iShares Biotechnology ETF
Anteil1.38%
First Trust International Equity Opportunities ETF
Anteil1.33%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten